Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$4.56 – $4.71
Volume4,350
Market cap$65M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$65.14M
Price / earnings
—
Price / book
16.73×
Price / sales
1.07×
EV / sales
1×
EV / EBITDA
151.57×
Profitability
Earnings per share
-$0.08
Return on assets
-3.32%
Return on equity
-28.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.03×
Quick ratio
1.03×
Cash ratio
0.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CSBR, quarterly periods
Line item
Q1 FY2027 Jul 31, 2026
Q4 FY2026 Apr 30, 2026
Q3 FY2026 Jan 31, 2026
Q2 FY2026 Oct 31, 2025
Q1 FY2026 Jul 31, 2025
Q4 FY2025 Apr 30, 2025
Q3 FY2025 Jan 31, 2025
Q2 FY2025 Oct 31, 2024
Revenue
$15.23M
$13.84M
$16.56M
$15.04M
$14M
$12.36M
$17.04M
$13.49M
Cost of revenue
$7.53M
$6.81M
$8.83M
$7.26M
$8M
$7.27M
$6.62M
$7.43M
Gross profit
$7.7M
$7.03M
$7.73M
$7.77M
$6M
$5.08M
$10.42M
$6.06M
Selling, general and administrative
$5.76M
$5.43M
$5.64M
$4.97M
$4.43M
$4.84M
$4.2M
$3.64M
Research and development
$2.34M
$2.12M
$2.27M
$2.62M
$2.08M
$1.96M
$1.72M
$1.69M
Total operating expenses
$8.11M
$7.55M
$7.91M
$7.59M
$6.53M
$6.8M
$5.92M
$5.33M
Operating income
-$409K
-$521K
-$187K
$185K
-$527K
-$1.71M
$4.5M
$732K
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$415K
-$495K
-$237K
$255K
-$452K
-$1.96M
$4.52M
$739K
Income taxes
$11K
$172K
$42K
$18K
$14K
-$129K
$23K
$11K
Net income
-$426K
-$667K
-$279K
$237K
-$466K
-$1.84M
$4.5M
$728K
Net income attributable to common shareholders
-$426K
-$667K
-$279K
$268K
-$466K
-$1.84M
$4.5M
$728K
EBITDA
-$95K
-$200K
$154K
$542K
-$169K
-$1.32M
$4.9M
$1.13M
Basic earnings per share
-$0.03
-$0.05
-$0.02
$0.02
-$0.03
-$0.13
$0.33
$0.05
Diluted earnings per share
-$0.03
-$0.05
-$0.02
$0.02
-$0.03
-$0.13
$0.31
$0.05
Recent news
Company coverage with links to the original publishers.
In a comparison of two oncology-focused healthcare companies, Champions Oncology (CSBR) is recommended as the better buy over Biodesix (BDSX). While BDSX has surged 156.7% over the past year, CSBR offers more attractive valuation metrics and better risk-reward positioning. CSBR benefits from strong demand for oncology research services, expanding data licensing opportunities, and radiopharmaceutical development initiatives. BDSX shows promise through lung diagnostic test adoption and operational improvements, but trades at a higher valuation with less upside potential.
Champions Oncology (CSBR) reported Q1 FY2027 revenues of $15.2 million, up 8.8% year-over-year, with improved margins and narrowed losses. However, the stock declined 1.8% post-earnings. The company saw strong growth in data-license revenues (up 187.1%) but faced headwinds from declining Other TOS revenues. Management emphasized continued investment in sales and marketing while pursuing funding or licensing partnerships for its Corellia platform.
Champions Oncology reported Q3 FY2026 results with record core study revenue of $16.6 million (up 32% YoY), but overall revenue declined 3% due to absence of data revenue. The company achieved its third consecutive quarter of positive adjusted EBITDA at $575,000. Gross margins fell to 47% from 61% due to $2M in outsourced radiolabeling costs. Management expects margin improvement as work moves in-house and anticipates full-year revenue growth and positive EBITDA, with early momentum in the data business including a 6-figure deal expected to recognize in Q4.
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Solid Biosciences
The Trade: Solid Biosciences Inc. (NASDAQ: SLDB) Director Joseph Edelman acquired a ...
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
General American Investors
The Trade: General American Investors Company, Inc. (NYSE: GAM) President and CEO ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.